Sinus implants

PROPEL™ (mometasone furoate) sinus implant

Sinus implants

PROPEL™ (mometasone furoate) sinus implant

The PROPEL™ sinus implant maintains patency and locally delivers steroid to the sinus mucosa in patients 18 years and older following sinus surgery.

Contact a representative
Indications, Safety, and Warnings

Description

Enhance your sinus action plan

PROPEL™ is the first and only methoxy propyl acetate (PMA)-approved steroid eluting sinus implant.1 The PROPEL™ family of implants offers three steroid-eluting implants, allowing ear, nose, and throat (ENT) physicians to select the best option that confirms to the anatomical needs of their patients:2–4

  • PROPEL™ mometasone furoate implant for ethmoid sinus2
  • PROPEL™ mini mometasone furoate implant for ethmoid sinus and frontal sinus opening3
  • PROPEL™ contour mometasone furoate implant for sinus ostia, frontal, and maxillary4

Features

PROPEL™ implants keep the sinuses open while releasing mometasone furoate (MF).

PROPEL™ implants feature an innovative two-in-one mechanism that opens in the sinuses while delivering MF, a potent corticosteroid, directly where it is needed.2–4

  • Self-expanding design that opens and supports the sinus cavity
  • Delivers 370 mcg of MF over 30 days†
  • Non-obstructive design allows for sinus mucociliary clearance and the delivery of topical rinses
  • MF present in the sinus mucosal tissue for up to 60 days5
  • Structural backbone bio-absorbs over approximately 30–45 days after placement as the sinus cavity heals

Mometasone furoate delivers a combination of potency and safety.

Drug characteristics comparison6–9

Topical corticosteroid Lipophilicity‡,6 Potency (receptor affinity)†,7 Systemic bioavailablity‡,8
Dexamethasone Very low (less than 1.0) Very low (100) High (76%)
Triamcinolone (Kenalog) Low (1.0) Low (233) Medium (46%)
Budesonide Low (1.6) Intermediate (935) Medium (34%)
Mometasone furoate High (20.0) High (2,300) Very low (less than 1%)

Optimal sinonasal drug characteristics7

Highly lipophilic

Readily absorbs into tissue

Targeted and potent

High glucocorticoid receptor affinity

Low systemic bioavailability

Minimize systemic effects

PROPEL™ implants are clinically proven to maintain patency and improve patient outcomes following endoscopic sinus surgery by targeting inflammation, the underlying cause of chronic rhinosinusitis.

The PROPEL™ sinus implants are intended to maintain patency and locally deliver steroid to the sinus mucosa in patients ≥18 years of age following sinus surgery: PROPEL™ for the ethmoid sinus, PROPEL™ Mini for the ethmoid sinus/frontal sinus opening, and PROPEL™ Contour for the frontal/maxillary sinus ostia. Contraindications include patients with confirmed hypersensitivity or intolerance to mometasone furoate (MF) or hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implant in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/ pressure, displacement of the implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection.

See full prescribing information (IFU).

Rx only.

† Lipophilicity numbers normalized relative to triamcinolone acetonide.

‡ As measured by relative receptor binding affinity compared to dexamethasone, which is set to a value of 100. Higher values designate greater potency.

  1. Food and Drug Administration. Approval order. Accessed June 28, 2019.
  2. PROPEL™ instructions for use. Menlo Park, CA: Intersect ENT; 2020.
  3. PROPEL™ mini instructions for use. Menlo Park, CA: Intersect ENT; 2020.
  4. PROPEL™ contour instructions for use. Menlo Park, CA: Intersect ENT; 2020.

  1. Li PM, Downie D, Hwang PH. Controlled steroid delivery via bioabsorbable stent: safety and performance in a rabbit model. Am J Rhinol Allergy. 2009;23(6):591–596.
  2. Lemke T, Williams D, Roche V, Zito SW, eds. Foye’s Principles of Medicinal Chemistry. 6th ed. Balitmore, MD: Lippincott Williams & Wilkins; 2008.
  3. Winkler J, Hochhaus G, Derendorf H. How the lung handles drugs: pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Thorac Soc. 2004;1(4):356–363.
  4. Sastre J, Mosges R. Local and systemic safety of intranasal corticosteroids. J Investig Allergol Clin Immunol. 2012;22(1):1–12.
  5. National Library of Medicine. PubChem. Dexamethasone. Accessed June 24, 2019.